Our Teams

Chairwoman and Chief Scientific Officer-CHANG YI WANG, Ph.D.

─ Chairwoman and Chief Scientific Officer ─

CHANG YI WANG, Ph.D.

    • United BioPharma (UBP), a spinoff company of UBI Asia, was founded by Dr. Chang Yi Wang. Dr. Wang serves as the executive Chairwoman of the Board of Directors and Chief Scientific Officer of UBP. At the invitation of the Taiwanese government in 1998, Dr. Wang set out to establish UBI-Asia, a joint venture between United Biomedical, Inc. (UBI) based in the US and the Taiwan government. She launched a state-of-the-art protein and antibody drug development platform within UBI Asia employing monoclonal antibody B4 as a touch stone and built a competent team with integrated platform technologies to enable development of antibody products from DNA to BLA filings. Other antibody and long acting protein products followed, leading to the spinoff of United Biopharma with a group of rigorously selected antibody products.

      Dr. Wang’s invention, UB421, is the first antibody product in UBP’s pipeline. UB421 is an anti CD4 antibody having a unique HIV competitive binding inhibition property. UB421 is currently in multiple Proof of Concept (POC) phase II trials in combination with ART for functional cure, as well as a multinational monotherapy phase III trial for ART substitution. With CD4 being an important immune modulatory molecule, this class of antibodies with characteristic features resembling UB421 have many important first-in-human clinical applications.

      In addition to antibody and long acting protein products as biologics for disease treatment, Dr. Wang is a pioneer in using designer synthetic peptides in multiple biomedical applications. Her early inventions in synthetic peptide based HIV and HCV blood screening tests have sold hundreds of millions in the global market; since 2007, her first high precision epitope based vaccine against Foot and Mouth Disease in the animal health field has sold over 4 billion doses in China, the largest global swine market; her second high precision peptide based LHRH targeted immunocastration vaccine has also been launched in the global swine market. These initial inventions have provided UBI with commercialization expertise to become an industry leader in many high precision peptide vaccine applications in disease intervention as immunotherapeutics.

      Dr. Wang has received several prestigious awards, including the 2007 Inventor of the Year award from the New York Intellectual Property Law Association (NYIPLA) for her high precision UBITh immunogen designs, and the 2018 Pioneer in Technology Award from the Brain Mapping Foundation for her contribution in the development of vaccines for the treatment of Neurodegenerative Diseases.

      Prior to founding UBI in 1985 and its subsequent group of companies to facilitate commercialization of her platform derived inventions, Dr. Wang was a Principal Investigator and director of the Laboratory of Molecular Immunology, endowed by the Arthur J. and Leslie Levine fund, at the Memorial Sloan-Kettering Cancer Center, a faculty member at the Sloan Kettering Institute and an adjunct associate professor at the Cornell University Medical School.

      During her research career in the US, she received over US$20 million in grants and contracts from National Institute of Allergy and Infectious Diseases (NIAID) and National Cancer Institute (NCI) of National Institutes of Health (NIH). Dr. Wang has over 120 scientific publications in peer-reviewed high impact journals such as New England Journal of Medicine, Lancet, Science, Journal of Experimental Medicine, and Journal of Infectious Diseases etc. and over 100 issued patents and additional pending patent filings. Dr. Wang received her B.S. in chemistry with honors from National Taiwan University and her Ph.D. in immunology and biochemistry from the Rockefeller University, New York, USA.

Chief Executive Officer and President-SHUGENE LYNN, Ph.D.

─ Chief Executive Officer and President ─

SHUGENE LYNN, Ph.D.

    • Dr. Shugene Lynn is the Chief Executive Officer and a member of the Board of Directors of United BioPharma (UBP). She also serves as a board member of several companies within the UBI group. Prior to joining UBP in January 2019, she was the executive vice president of corporate development at UBI Asia, responsible for corporate strategic planning and financing.

      She has been with the UBI group since 1999, beginning as a bench scientist with increasing responsibility from project to program management, to corporate development, and has been associated with every step along the path of UBI growth in Asia. She was the first scientist in the UBI group to be engaged in the antibody humanization platform, and has since led a team to build the therapeutic monoclonal antibody process development platform, and brought the HIV drug candidate UB-421 from cell line development to clinical phase I and II stages. During her tenure at UBI Asia, the company was awarded 11 government research grants, and sponsored three monoclonal antibody drug candidates into clinical trials.

      Dr. Lynn received her B.S. in plant pathology and Ph.D. in life sciences from the Institute of Zoology both from National Taiwan University. She completed her postdoctoral training at Academia Sinica and received the Outstanding Postdoctoral Fellow Award in 1998 for her eight first author publications in international journals.

Executive Vice President, Product Development-MEIJUNE LIAO, Ph.D.

─ Executive Vice President, Product Development ─

MEIJUNE LIAO, Ph.D.

    • Dr. Liao is currently Executive Vice President of Product Development and a member of the Board of Directors at United BioPharma (UBP). She served as the President of UBP during its formative stage from 2014 to 2018. Dr. Liao has over 35 years’ experience in the biopharmaceutical industry. Prior to joining UBP in January 2014, she was vice president of UBI, responsible for regulatory affairs for biological products and was a key member in UBI’s NIH-funded HIV Therapeutic Vaccine program. From 2003 to 2007, she was vice president of research & development and quality control for Hemispherix Biopharma, Inc., responsible for product development for natural leukocyte interferon (Alferon®) and therapeutic RNA (Ampligen®). She also served from 1983 to 2003 at Interferon Sciences, from a bench scientist with increasing responsibilities to vice president of research and development, where she directed all R&D projects in the major areas of protein biochemistry, cell biology, and molecular biology. Dr. Liao is accomplished in the development of therapeutic biological products, from research to preclinical testing, human clinical trials, and final approval by the US FDA and other regulatory agencies.

      She received her B.S. in chemistry from National Tsing Hua University, in Taiwan, her M.S. and Ph.D. in physical biochemistry from Yale University. Dr. Liao completed postdoctoral training at Massachusetts Institute of Technology under the direction of Nobel Laureate Professor H. Gobind Khorana. She is the author of numerous publications and holds several patents in the area of alpha interferons.

Chief Financial Officer and Corporate Secretary-Keith Lau

─ Chief Financial Officer and Corporate Secretary ─

Keith Lau

    • Mr. Keith Lau is Chief Financial Officer and Company Secretary at United BioPharma Holdings Co., Ltd; he is Vice President of Finance at United BioPharma Inc. (UBP). Mr. Lau joined United BioPharma from Luoxin Pharmaceutical Group Stock Co. Ltd., where he has served as Financial Controller and Company Secretary.

      Mr. Lau’s finance experience includes financial control, auditing, corporate governance, advice on IPO and listed company management. he assisted Luoxin Pharma’s IPO for listing on Hong Kong Exchange in 2003 which was subsequently privatized in 2017. Mr. Lau is also the Independent Non-Executive Director of two listed financial and technology corporations. Earlier in his career, he served as consultant for sizable accounting firm and sponsors for various corporations’ IPO projects.

      With an impressive CPA certification from Australia and FCPA from Hong Kong, Mr. Lau has obtained Master of Professional Accounting from Hong Kong Polytechnic University and Bachelors of Commerce from Australian National University

President, UBP, Yangzhou-XINGTIAN YAO

─ President, UBP, Yangzhou ─

XINGTIAN YAO

    • Xingtian Yao is the President for United BioPharma’s Yangzhou subsidiary which is the base for center of excellence in product development and manufacturing in China.

      Prior to joining United BioPharma, Mr. Yao was the chairman and CEO of a Shanghai A Stock Board listed Lian Huan Pharma Inc. which is a subsidiary of Lian Huan Pharma Group of Companies based in Yanzhou which he joined right after his graduation with BS in China Pharmaceutical University. He began his career at Lian Huan Pharma group in the early 80s as a supervisor in a pilot API (Active Pharmaceutical Ingredient) plant and assumed increasing leadership roles and responsibilities over the years to help the establishment of many joint ventures and subsidiaries to build the original Lian Huan Pharma company into a group of companies.

      During his tenure at Lian Huan Pharma group, he served as vice president and president; Mr. Yao took the role of president of a few affiliates or joint venture entities within the Lian Huan Pharma Group such as Yangzhou Yang-Da Lian Huan Genetic Engineering Ltd.and Shangxi Datong Tongxing Antibiotics Corporation Ltd. In addition, Mr. Yao served as vice president Jiangsu Jinmao Chemistry Pharma group.

      XingTian received an honorary award from Yangzhou City Government and the Pharmaceutical Industry of the Jiangsu Province as a model employee in 1995. Mr. Yao was a member of the board of directors of Nanking University.

Board of Directors

  • United BioPharma (UBP), a spinoff company of UBI Asia, was founded by Dr. Chang Yi Wang. Dr. Wang serves as the executive Chairwoman of the Board of Directors and Chief Scientific Officer of UBP. At the invitation of the Taiwanese government in 1998, Dr. Wang set out to establish UBI-Asia, a joint venture between United Biomedical, Inc. (UBI) based in the US and the Taiwan government. She launched a state-of-the-art protein and antibody drug development platform within UBI Asia employing monoclonal antibody B4 as a touch stone and built a competent team with integrated platform technologies to enable development of antibody products from DNA to BLA filings. Other antibody and long acting protein products followed, leading to the spinoff of United Biopharma with a group of rigorously selected antibody products.

    Dr. Wang’s invention, UB421, is the first antibody product in UBP’s pipeline. UB421 is an anti CD4 antibody having a unique HIV competitive binding inhibition property. UB421 is currently in multiple Proof of Concept (POC) phase II trials in combination with ART for functional cure, as well as a multinational monotherapy phase III trial for ART substitution. With CD4 being an important immune modulatory molecule, this class of antibodies with characteristic features resembling UB421 have many important first-in-human clinical applications.

    In addition to antibody and long acting protein products as biologics for disease treatment, Dr. Wang is a pioneer in using designer synthetic peptides in multiple biomedical applications. Her early inventions in synthetic peptide based HIV and HCV blood screening tests have sold hundreds of millions in the global market; since 2007, her first high precision epitope based vaccine against Foot and Mouth Disease in the animal health field has sold over 4 billion doses in China, the largest global swine market; her second high precision peptide based LHRH targeted immunocastration vaccine has also been launched in the global swine market. These initial inventions have provided UBI with commercialization expertise to become an industry leader in many high precision peptide vaccine applications in disease intervention as immunotherapeutics.

    Dr. Wang has received several prestigious awards, including the 2007 Inventor of the Year award from the New York Intellectual Property Law Association (NYIPLA) for her high precision UBITh immunogen designs, and the 2018 Pioneer in Technology Award from the Brain Mapping Foundation for her contribution in the development of vaccines for the treatment of Neurodegenerative Diseases.

    Prior to founding UBI in 1985 and its subsequent group of companies to facilitate commercialization of her platform derived inventions, Dr. Wang was a Principal Investigator and director of the Laboratory of Molecular Immunology, endowed by the Arthur J. and Leslie Levine fund, at the Memorial Sloan-Kettering Cancer Center, a faculty member at the Sloan Kettering Institute and an adjunct associate professor at the Cornell University Medical School.

    During her research career in the US, she received over US$20 million in grants and contracts from National Institute of Allergy and Infectious Diseases (NIAID) and National Cancer Institute (NCI) of National Institutes of Health (NIH). Dr. Wang has over 120 scientific publications in peer-reviewed high impact journals such as New England Journal of Medicine, Lancet, Science, Journal of Experimental Medicine, and Journal of Infectious Diseases etc. and over 100 issued patents and additional pending patent filings. Dr. Wang received her B.S. in chemistry with honors from National Taiwan University and her Ph.D. in immunology and biochemistry from the Rockefeller University, New York, USA.

  • Dr. Shugene Lynn is the Chief Executive Officer and a member of the Board of Directors of United BioPharma (UBP). She also serves as a board member of several companies within the UBI group. Prior to joining UBP in January 2019, she was the executive vice president of corporate development at UBI Asia, responsible for corporate strategic planning and financing.

    She has been with the UBI group since 1999, beginning as a bench scientist with increasing responsibility from project to program management, to corporate development, and has been associated with every step along the path of UBI growth in Asia. She was the first scientist in the UBI group to be engaged in the antibody humanization platform, and has since led a team to build the therapeutic monoclonal antibody process development platform, and brought the HIV drug candidate UB-421 from cell line development to clinical phase I and II stages. During her tenure at UBI Asia, the company was awarded 11 government research grants, and sponsored three monoclonal antibody drug candidates into clinical trials.

    Dr. Lynn received her B.S. in plant pathology and Ph.D. in life sciences from the Institute of Zoology both from National Taiwan University. She completed her postdoctoral training at Academia Sinica and received the Outstanding Postdoctoral Fellow Award in 1998 for her eight first author publications in international journals.

  • Dr. Liao is currently Executive Vice President of Product Development and a member of the Board of Directors at United BioPharma (UBP). She served as the President of UBP during its formative stage from 2014 to 2018. Dr. Liao has over 35 years’ experience in the biopharmaceutical industry. Prior to joining UBP in January 2014, she was vice president of UBI, responsible for regulatory affairs for biological products and was a key member in UBI’s NIH-funded HIV Therapeutic Vaccine program. From 2003 to 2007, she was vice president of research & development and quality control for Hemispherix Biopharma, Inc., responsible for product development for natural leukocyte interferon (Alferon®) and therapeutic RNA (Ampligen®). She also served from 1983 to 2003 at Interferon Sciences, from a bench scientist with increasing responsibilities to vice president of research and development, where she directed all R&D projects in the major areas of protein biochemistry, cell biology, and molecular biology. Dr. Liao is accomplished in the development of therapeutic biological products, from research to preclinical testing, human clinical trials, and final approval by the US FDA and other regulatory agencies.

    She received her B.S. in chemistry from National Tsing Hua University, in Taiwan, her M.S. and Ph.D. in physical biochemistry from Yale University. Dr. Liao completed postdoctoral training at Massachusetts Institute of Technology under the direction of Nobel Laureate Professor H. Gobind Khorana. She is the author of numerous publications and holds several patents in the area of alpha interferons.

  • Mr. James Chui was elected to the board of Directors of United BioPharma in July 2018. He is currently the Chairman of a number of companies, including Sino-Pacific Agency Partner (Hong Kong) Ltd,, Excellence Raise Oversea Ltd, and a non-executive chairman of Tornado Global Hydrovacs Ltd, a board member of Empire Industrials Ltd.(Canada), Beijing You-Peng Technology Co., Ltd,. and United Neuroscience LLC.(UNS).

    Mr. Chui began his business career in Asia and is well acquainted with Sino–American business affairs. He has over 30 years’ experience in business operations, as entrepreneur and investor, specializing in identifying growth opportunities, financing and structuring alliances for private and public companies.

    His extensive experience in business has provided him with a keen sense to effectively and efficiently assess, initiate and operate large scale projects globally.

    Mr. Chui graduated from China University of Science and Technology with a major in material science. Currently, he is also a visiting scholar and faculty member in Economics at FuDan University in Shanghai. China.

Scientific Advisors And Clinical Partners

  • Dr. Carl V. Hanson is the Head of the Retrovirus Diagnostics Section of the Viral and Rickettsial Disease Laboratory of the California Department of Health Services, Richmond, CA, which serves as California’s reference laboratory for HIV diagnostics. Dr. Hanson is also a faculty member of the University of California, Berkeley. He has been the Principal Investigator of grants from NIH and the U.S. Army for the development and evaluation of HIV vaccines and the study of HIV virology, immunology and serology. He earned his Ph.D. in Biophysics from Harvard University.

    In 1994, Dr. Hanson was the first to observe that experimental AIDS vaccines based on laboratory-adapted HIV strains evoked little or no neutralizing antibodies to protect patients from infection, thereby overturning all previous work done worldwide on HIV vaccines. He serves as a scientific advisor and collaborator with UBI and its affiliate United BioPharma, and has applied his laboratory’s state-of-the-art neutralization assays to UBI’s anti-host cell approach for the development of effective HIV immunotherapeutics. Dr. Hanson is an author and co-author of over 70 scientific publications. He is a reviewer for NIH and several AIDS journals, and the Chairman of the “Neutralization Task Force” for the International AIDS Vaccine Initiative (IAVI).

  • Dr. Flossie Wong-Staal is an internationally recognized leader in virology and one of the pioneers in AIDS research. She is the Vice President and Chief Scientific Officer for Genomics at Immusol, which was rebranded as iTherX Pharmaceuticals in 2002 to reflect its transition to an HCV focus. She earned her Ph.D. in molecular biology in 1972 from UCLA. In 1973, Dr. Wong-Staal moved to Bethesda, Maryland to work at the National Cancer Institute (NCI) to pursue then-new molecular biology techniques that revealed the workings of cells at the molecular and genetic level. While there, Dr. Wong-Staal was amongst the first researchers to clone and decipher the HIV genome in 1985 which led to the first genetic map of the virus, allowing for the characterization of the functional proteins of the virus. In 1990, Dr. Wong-Staal joined UC San Diego to continue her AIDS research and became the chairwoman of the newly opened Center for AIDS Research. In 2002, Discover Magazine named Dr. Wong-Staal one of the fifty most extraordinary women scientists. Wong-Staal remains as a Chaired Research Professor of Medicine at UCSD. For her contributions to science, the Institute for Scientific Information named Dr. Wong-Staal the top woman scientist of the 1980s. In 2007, The Daily Telegraph heralded Dr. Wong-Staal as #32 of the "Top 100 Living Geniuses."

  • Dr. Jeffrey Jacobson is a world-renowned HIV clinical researcher. He is the Professor of Medicine and Neuroscience, at Lewis Katz School of Medicine at Temple University. His research work specializes in Infectious Diseases. He has chaired numerous clinical research studies involving the pathogenesis, pharmacokinetics and treatment of HIV for both intra and extramural clinical research at the National Institutes of Health (NIH)-sponsored AIDS Clinical Trials Group (ACTG). He has also chaired several ACTG committees, including the Immunology Committee and the Translational Research and Drug Development Committee, and has been a member of the Scientific Agenda Steering Committee of the ACTG. He has 118 peer-reviewed publications in high impact journals such as New England Journal of Medicine, Lancet, Nature Medicine, Journal of Infectious Diseases and Annals of Internal Medicine. He earned many honors, including placement on the list of the “Top Doctors in America”, “Best Doctors in America”, and the Clinical Research Scientist Award and Honored Member of Strathmore’s “Who’s Who.” Dr. Jacobson received his M.D. from Cornell University Medical College and completed his residency and fellowship training at Mount Sinai Medical Center, New York.

  • Dr. Chun is our collaborator on UB-421 clinical development. He is currently the Chief of the HIV Immunovirology Unit at the National Institute of Allergy and Infectious Diseases (NIAID), of National Institutes of Health (NIH).

    Dr. Chun received his Ph.D. from the biochemistry, cellular, and molecular biology graduate program from Johns Hopkins University School of Medicine where he discovered and characterized latently infected, resting CD4+ T cells in HIV-infected individuals. Dr. Chun began his postdoctoral research work in the Laboratory of ImmunoRegulation (LIR) under Dr. Anthony Fauci at NIAID in 1997. He was the first to demonstrate that the latent HIV reservoir persists in virtually all infected individuals receiving antiretroviral therapy despite effective suppression of plasma viremia. In addition, he demonstrated that early initiation of antiretroviral therapy leads to a decay of the latent viral reservoir and introduced the concept of “virus purging” in HIV-infected individuals.

    Dr. Chun was appointed to the position of staff scientist in 2001, and was selected as one of the Earl Stadtman Investigators, and appointed a tenure track investigator position in the LIR in June 2016. Dr. Chun is the author/coauthor of numerous peer-reviewed publications in high impact journals such as New England Journal of Medicine and Nature Medicine, and participated in several pioneering clinical trials in HIV treatment.

  • Dr. Mathias Lichterfeld is an Infectious Disease Physician at the Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) in Boston, and an Associate Professor of Medicine at Harvard Medical School. He received both his M.D. and Ph.D. degrees from the University of Heidelberg, Germany, and completed residency and infectious disease fellowship training at MGH and BWH. His research focuses on understanding the mechanisms of natural control of HIV-1 infection in “elite controllers”, and on developing clinical strategies that may lead to long-term drug-free remission of HIV-1 infection in a broader patient population.

  • Dr. Hao Wu is currently the Chief of Infectious Diseases Department of Beijing Youan Hospital, Capital University of Medical Sciences (首都医科大学附属北京佑安医院). He is also the professor of Capital Medical University.

    Dr. Wu has been conducting research in the area of Infectious Diseases for more than 25 years. He has made extensive scientific and medical contributions in HIV/AIDS public health and clinical arena and is a renowned HIV research expert in China. Dr. Wu is the founder of the Beijing Acute HIV Infection Cohort Study which is the largest cohort among MSM (Men who have Sex with Men) population in China and also serves on the panel of experts in HIV treatment, organized by Ministry of Health, China.

    Dr. Wu has edited 5 books, wrote numerous chapters for textbooks of infectious diseases, and is an author/co-author of over 100 scientific publications. Dr. Wu received his M.D. in Infectious Diseases from Capital University of Medical Sciences in 1993.

  • Dr. Chang is an immunology researcher, whose career spans across academia and industry. His early research in the Immunoglobulin E (IgE) pathway and antibody-based therapeutics led to the development of omalizumab (Xolair®), a highly successful mAb medicine that has been approved for the treatment of severe allergic asthma and severe chronic spontaneous urticarial (CSU). He is also a co-inventor of the advanced generation anti-IgE mAb, UB-221.

    Dr. Chang is the co-founder of Tanox, a biopharmaceutical company specialized in anti-IgE therapies for the treatment of allergic diseases and acquired by Genentech. Dr. Chang returned to his alma mater National Tsing Hua University in Taiwan in 1996 and served as the Dean (1996–1999) of the College of Life Sciences. Dr. Chang was appointed by the Taiwanese government as the Chief Executive Officer of the Development Center for Biotechnology (DCB) in 2000, and served as a Science and Technology Advisor of the Executive Yuan from 2002 to 2006. From 2006 to 2016, he was tenured as a Distinguished Research Fellow at the Genomics Research Center, Academia Sinica, and a distinguished Visiting Chair of Genomics Research Center at Academia Sinica since 2016. He founded Immunwork, Inc. in 2014. Dr. Chang received both his B.S. and M.S. in chemistry from National Tsing Hua University in 1972 and obtained his Ph.D. in cell and developmental biology from Harvard University in 1977. He completed his postdoctoral fellow training at Center for Cancer Research, M.I.T., from 1977 to 1980.

  • Dr. Anna Wald is our Principal Investigator for anti-HSV mAb UB-621’s phase II clinical trial in U.S. Dr. Wald is a board certified physician in both Internal Medicine and Infectious Disease and the director of the University of Washington (UW)’s Virology Research Clinic at Harborview. She is also a professor of Medicine, Epidemiology and Laboratory Medicine at University of Washington. She is a fellow of American College of Physician and Infectious Diseases Society of America. Her clinical and research interests include infectious diseases, clinical virology, sexually transmitted infections, and infection in immunocompromised persons, epidemiology and vaccines for herpes virus infections.

    Dr. Wald received her M.D. from Icahn School of Medicine at Mount Sinai Medical School and has been in practice for more than 20 years.

  • Dr. Cohen is currently the Chief of Laboratory of Infectious Diseases and also Chief in Medical Virology at NIAID, NIH. He received his M.D. from The Johns Hopkins University and was a resident in medicine at Duke University. Following a medical staff fellowship at NIH, he was a clinical fellow in infectious diseases at the Brigham and Women’s Hospital and an instructor in medicine at the Harvard University. Dr. Cohen is a world expert on human herpes viruses studies, including Epstein-Barr virus (EBV), herpes simplex virus (HSV), varicella-zoster virus (VZV), and cytomegalovirus (CMV). Dr. Cohen is collaborating with UBP on evaluation of the neutralizing ability of UB-621 against HSV-1 and HSV-2 clinical isolates and the strains resistant to approved anti-HSV drugs. He also participates actively in many clinical trials including a Phase I study of a replication defective herpes simplex virus vaccine, study of patients with severe viral infections to define genetic variants associated with the disease, study of patients with EBV diseases, study with a respiratory syncytial virus challenge, and attempts to identify novel viruses in patients with unexplained syndromes.

  • Dr. Pamela Guerrerio graduated with a B.S. degree in biology from the University of Iowa and received her Medical Scientist Training Program at Johns Hopkins University, where she received both her M.D. and a Ph.D. in human genetics. She also did her residency in pediatrics and fellowship in allergy and immunology at Johns Hopkins. She subsequently joined the faculty at Johns Hopkins University and was the recipient of the 2011 ARTrust Faculty Development Award from the American Academy of Asthma, Allergy & Immunology. In 2014, Dr. Guerrerio was appointed chief of the Food Allergy Research Unit at National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH),

  • Dr. Hung-Chin Tsai is the Principal Investigator of UB-421’s cART substitution, phase III clinical trial in Taiwan. He currently serves as the Director of Infection Control Unit of Kaohsiung Veteran General Hospital, an Attending Physician at the Infection Disease Division of Kaohsiung Veteran General Hospital, and an Associate Professor of Internal Medicine at the Department of Medicine, National Yang-Ming University.

    From 1999 to 2001, he completed all his medical training at Kaohsiung Veteran General Hospital from a resident to an attending physician at the Internal Medicine and Infectious Disease Division. Dr. Tsai has authored and co-authored over 90 papers in scientific journals.

    Dr. Tsai holds an M.D. from Kaohsiung Medical University, School of Medicine and received his Ph.D. from Kaohsiung Medical University Medical Research Institute in 2007.

  • Dr. Han-Chung Wu is currently the Research Fellow of Institute of Cellular and Organismic Biology, Academia Sinica, a professor of Institute of Pathology and Graduate Institute of Oral Biology, National Taiwan University (NTU) and a Joint Research Fellow at Genomics Research Center of Academia Sinica since 2010. His research interest lies in the identification of cancer-specific ligands and development of ligand-mediated target therapy and molecular imaging.

    Dr. Wu is the author of more than 30 scientific publications and was awarded a number of academic honors, including Academia Sinica Young Investigator Award in 2008 (2008年中央研究院年輕學者研究著作獎), NSC Outstanding Research Award, National Science Council, Taiwan in 2011 (2011 國科會傑出研究獎), MOST Outstanding Research Award, Ministry of Science and Technology, Taiwan in 2015 (2015 科技部傑出研究獎) and International Inventor Prize and Lifetime Achievement Academic Award in 2018 (2018第十四屆IIP國際傑出發明家終身成就獎).

    Dr. Wu received his Ph.D. from Institute of Pathology, National Taiwan University in 1993.

  • Jeffery Jacobson, MD
    • Professor, Infectious diseases, Drexel University, PA
    • Chaired numerous clinical research studies involving the pathogenesis, pharmacokinetics and treatment of HIV inside and outside of the NIH-sponsored AIDS Clinical Trials Group (ACTG).
    • Chaired several ACTG committees, including the Immunology Committee and the Translational Research and Drug Development Committee.
  • Flossie Wong-Staal, PhD
    • Chairman of Center for AIDS Research, UC San Diego
    • The first scientist to clone HIV and determine the function of its genes, a major step in proving that HIV is the cause of AIDS.
    • Held the Florence Riford Chair in AIDS Research at the University of California at San Diego (1990~2002).
  • Clinical trial investigators
    • AIDS therapeutic mAb UB-421

      Taipei Veterans General Hospital: Dr. Yung-Wei Wang
      Kaohsiung Veterans General Hospital: Dr. Hung-Chin Tsai
      Chung-Ho Memorial Hospital: Dr. Yen-Hsu Chen
      National Taiwan University Hospital: Dr. Sz-Min Hsieh
      Tri-Service General Hospital: Dr. Ning-Chi Wang
      Far Eastern Memorial Hospital: Dr. Chia-Jui Yang
      Kaohsiung Chang Gung Memorial Hospital: Dr. Chen-Hsiang Li

    • Anti-HSV mAb UB-621

      Taipei Veterans General Hospital: Dr. Yung-Wei Wang

    • Herceptin® biosimilar UB-921

      Tri-Service General Hospital: Dr. Hsiang-Cheng Chen

    • Anti-IgE mAb UB-221

      National Taiwan University Hospital: Dr. Chia-Yu Chu

  • Hao Wu, MD
    • Professor of Capital University of Medical Sciences and Chief of Department of Infectious Diseases in the University Hospital and Beijing Youan Hospital
    • Founder of the Beijing Acute HIV Infection Cohort Study, which is the largest cohort among MSM population in China
    • National specialist in HIV/AIDS field, Ministry of Public Health
    • Received M.D.degree in Infectious Diseases (1993) from Capital University of Medical Sciences
  • Daniel Kuritzkes, MD
    • Professor, Harvard Medical School, Brigham & Women’s Hospital Hospital
    • Served on numerous NIH committees
    • Chaired the HIV Disease Research Agenda Committee of the Adult AIDS Clinical Trials Group.
  • Medical Science Consultants (Chang Gung Memorial Hospital)
    • Tzu-Chen Yen, MD, PhD
      1. Director of Department for Advanced Molecular Imaging and Translation
      2. Attending physician (professor level) of Nuclear Medicine
      3. Director of Development and Planning Center
      4. Director of Industry-University Collaboration Center
      5. Professor of Department of Medicine, Chang Gung University
    • Jian-Tai Qui, MD, PhD
      1. Attending physician of Gynecologic Oncology
      2. Associate professor in Chang Gung University
    • Ming-Xun Li, MD, PhD
      1. Attending physician of Infectious Diseases
    • Wei-Li Chen, Chief Pharmacist
      1. Senior Administrator of Medical Business Development Center in Formosa Plastics Group
      2. IRB committee of Chang Gung Medical Group
    • Shu-Fen Lo, MD, PhD
      1. Attending physician and clinical professor of Rheumatology and Immunology
  • PhD
    • Staff Scientist, NIH/NIAID, Laboratory of immunoregulation
    • The lead investigator of the NIH program on persistent viral reservoirs in the pathogenesis and treatment of HIV disease.
  • PhD
    • Head of the Retrovirus Diagnostics Section of the Viral and Rickettsial Disease Laboratory of the California Department of Health Services
    • A faculty member of the University of California, Berkeley.
    • The reviewer for NIH and several prominent AIDS journals.
    • The chairman of the "Neutralization Task Force" for the International AIDS Vaccine Initiative (IAVI).